IDH1 and central nervous system cancer: WHO grade IV gliomas are the most malignant and are associated with shorter median and overall survival times, and patients with gliomas carrying IDH mutations and 1p/19q co‐deletions achieve better survival than do those with IDH wildtype and no 1p/19q co‐deletions.6, 7